Literature DB >> 31053356

Transition of patients with neuromuscular disease and chronic ventilator-dependent respiratory failure from pediatric to adult pulmonary care.

Pi Chun Cheng1, Howard B Panitch2, John Hansen-Flaschen3.   

Abstract

Improvements in medical care have allowed many children with neuromuscular disease and chronic respiratory failure to survive into adulthood. There are currently no published guidelines to facilitate transition from pediatric to adult respiratory care in this population. The transition process in neuromuscular disease and chronic respiratory failure is uniquely challenging in that the patients are often declining in health and losing independence as they approach adulthood. Barriers to transition include lack of access to adult providers, incompatible health insurance, loss of resources within patients' medical structures, absence of transition preparation, and patient and family insecurity with a new healthcare system. The six core elements and optimal time frame of transition should be applied, with special consideration of the psychosocial aspects associated with neuromuscular disease. Successful transition revolves around information, open communication between young adults and their medical care team, and individualized planning to ensure optimal health and quality of life.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Mechanical ventilation; Noninvasive ventilation; Tracheostomy; Transition medicine

Year:  2019        PMID: 31053356     DOI: 10.1016/j.prrv.2019.03.005

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  2 in total

Review 1.  The adult multidisciplinary respiratory neuromuscular clinic.

Authors:  Neeraj M Shah; Patrick B Murphy; Georgios Kaltsakas
Journal:  Breathe (Sheff)       Date:  2020-09

2.  A novel generalized fuzzy intelligence-based ant lion optimization for internet of things based disease prediction and diagnosis.

Authors:  Ankit Verma; Gaurav Agarwal; Amit Kumar Gupta
Journal:  Cluster Comput       Date:  2022-02-24       Impact factor: 2.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.